RedHill Biopharma (RDHL) Tops Q3 EPS Views; Announces RIZAPORT Marketing Approval in Germany
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
RedHill Biopharma Reports Results for the Third Quarter of 2015
November 9, 2015 7:00 AM ESTKey Highlights Include:
A strong cash position of approximately $64 million at the end of the third quarter of 2015 following the Company's July 2015 public offering in the U.S. with gross proceeds of $44.5 million Recent key milestones include the first European marketing approval of RIZAPORT announced today, positive top-line results from the Phase I study with YELIVA (ABC294640) in advanced solid tumors and the initiation of a Phase I/II study with YELIVA for diffuse large B-cell lymphoma RedHill continues to advance the... MoreRedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
November 9, 2015 6:00 AM ESTThe German Federal Institute for Drugs and Medical Devices (BfArM) has granted national marketing approval for RIZAPORT (RHB-103) for the treatment of acute migraines under the European Decentralized Procedure (DCP) RedHill and IntelGenx continue their close cooperation in order to obtain approvals in additional European countries and in the U.S., where a New Drug Application (NDA) was submitted and a Complete Response Letter was received RedHill and IntelGenx continue to advance their activities to secure commercialization partners in Europe, the U.S. and additional territories... More
